Company News »

BIND Therapeutics to Present at Cowen & Co. 35th Annual Healthcare Conference

Business Wire
Share on StockTwits
Published on

BIND Therapeutics, Inc. (NASDAQ:BIND) , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Andrew Hirsch, BIND’s chief operating officer and chief financial officer, will present at the Cowen & Co. 35th Annual Healthcare Conference in Boston on Tuesday, March 3, 2015 at 10:40 a.m. ET.

Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at The webcasts will be archived on the BIND Therapeutics website following the event for one week.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering(R) platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd. and Merck (known as Merck Sharp & Dohme outside the United States and Canada) to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the Company’s web site at

Share on StockTwits